Press Kits - AMS II Fact Sheet

Fact Sheet
A new study conducted for the National Headache Foundation (NHF) and underwritten by a grant from Glaxo Wellcome Inc. (now GlaxoSmithKline) measures the prevalence of migraine headache in America and quantifies the impact this disabling disease has on the lives of migraine sufferers. The study shows most patients are not receiving optimal treatment. In a startling comparison between the new data and that of a similar study conducted in 1989, it was found that despite the development of medications specifically designed to treat migraine over the last decade, patient treatment has not kept pace with scientific breakthroughs.

Migraine is a legitimate, biological disease characterized by throbbing head pain, usually located on one side of the head, often accompanied by nausea and sensitivity to light and/ or sound. Migraine is more common than asthma, diabetes or congestive heart failure. The combination of disabling pain and associated symptoms often prevents sufferers from performing daily activities. Attacks occur periodically and can last from four to 72 hours. Symptoms, incidence and severity vary by individual and by attack.

Study Objectives

  • Measure the prevalence of migraine headaches in the American population
  • Assess the impact of migraine headaches on the daily lives of patients
  • Measure changes in migraine management between 1989 and 1999

Study Methods

  • The mail survey was conducted by Strategic Insights, Inc., using the National Family Opinion (NFO) household panel constructed to match national demography.
  • A 20-item symptom screening and impact questionnaire was mailed to 20,000 U.S. households in Spring 1999.
  • 13,869 completed questionnaires were returned (a 69.3percent response rate) and included data for 29,258 individuals aged 12 and older. A total of 6,211 severe headache sufferers were identified.
  • This study replicates methods used in the 1989 American Migraine Study, results published by Stewart, Lipton et. al in JAMA, 1992, Vol. 267, No. 1, pages 64-69.
  • The migraine symptom criteria of the International Headache Society (IHS) were used to identify potential migraineurs.

Summary of findings
There are nearly 28 million people in the United States aged 12 and older - nearly 13 percent of the population - suffering from headaches that fit the medical definition of migraine established by the IHS. This means one in every four U.S. households has a migraine sufferer. More than half of these sufferers have never received a physician diagnosis and most are not receiving the most appropriate treatment, despite new and effective therapies designed specifically to treat the pain and symptoms of migraine. There have been no dramatic changes in the way physicians approach the treatment of migraine in the last ten years.

Key Findings

  • Total U.S. migraine prevalence was virtually the same in 1999 (12.6 percent of the total population aged 12 and older) vs. 1989 (12.1 percent). However, the total number of sufferers has increased from 24 million in 1989 to 28 million in 1999.
  • One out of every four U.S. households has a migraine sufferer. Since there have been significant advances in treatment, including the development of migraine specific therapies over the past 10 years, one might think the medical approach to migraine would have changed dramatically in that time. It has not. Six out of 10 sufferers continue to use over-the-counter (OTC) remedies exclusively to manage their headaches. It also suggests physicians have not significantly changed their approach to migraine treatment despite the introduction of migraine specific therapies.
  • The continued high use of OTCs is even more surprising given the significant increase in the number of sufferers reporting a physician diagnosis (39 percent in 1989 vs. 48 percent in 1999).
  • Even diagnosed patients report a similar pattern of suffering compared with their undiagnosed counterparts, which highlights that appropriate treatment is a vital component of care. Patients report these symptoms:
    • Throbbing pain (85 percent diagnosed vs. 85 percent undiagnosed)
    • Sensitivity to light (89 percent diagnosed vs. 72 percent undiagnosed)
    • Pain on one side of the head (64 percent diagnosed vs. 55 percent undiagnosed)
    • Nausea (80 percent diagnosed vs. 66 percent undiagnosed)
  • Many patients continue to suffer needlessly:
    • 80 percent of migraine sufferers say their headaches are severe or extremely severe
    • 41 percent of migraine sufferers report headache pain five or more days in the last three months
    • Migraine is misdiagnosed as tension (a catch-all phase) or sinus headache (a relatively rare condition) almost as frequently as it is correctly diagnosed
    • 39 percent of all migraine sufferers report migraine pain so severe they are forced to retreat to their beds – sometimes for days at a time
    • 38 percent suffer three years or more before being diagnosed with migraine by a physician
    • More than half (51 percent) of sufferers report a 50 percent or more reduction in work and/or school productivity; 66 percent report a 50 percent or more reduction in household work productivity
    • 24 percent of migraine sufferers report headaches so severe that they have sought emergency room care

Mary Franklin
Director of Operations
National Headache Foundation

Give the gift of
pain relief

Your donation goes to work immediately, helping the NHF in our continuing effort to educate and fund valuable headache research.

Donate Now

Stay Connected


“I do greatly enjoy the NHF Newsletter. It has been a blessing to me to realize I’m not alone and that others are working hard to help those of us who suffer.”

Michael H.


NHF Facebook